1. Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer
   Jeyshka M. Reyes-González et al, 2020, Cancers CrossRef
2. ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer
   Huanhuan Chen et al, 2023, Journal for ImmunoTherapy of Cancer CrossRef
3. Comprehensive Analysis of Molecular Subtypes and Hub Genes of Sepsis by Gene Expression Profiles
   Yongxing Lai et al, 2022, Frontiers in Genetics CrossRef
4. ANKRD22 promotes M2 polarization in lung adenocarcinoma macrophages via the glycolytic pathway
   Jiangbo Cao et al, 2024, Chemical Biology & Drug Design CrossRef